The global cell culture media market is projected to USD 10.3 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 16.0 % between 2021 and 2026. The growth of this market is majorly driven by the rising R&D spending in pharmaceutical companies, emerging cell culture technologies for cell-based vaccines, increasing demand for monoclonal antibodies, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalized medicine. On the other hand, expensive cell biology research products and ethical concerns regarding cell biology research are expected to hinder the growth of this market.
The global cell culture media market is a consolidated market, with Thermo Fisher Scientific (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US) together accounting for ~50–60% of the global market.
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific (US) provides cell culture products, including cell culture media, through its Life Sciences Solutions and Specialty Diagnostics segments. The company has a strong geographic footprint and operates in more than 150 countries across North America, Europe, Latin America, and Asia. From 2019 to 2021, Thermo Fisher launched 4 cell culture media products, including the Gibco CTS NK-Xpander Medium, Gibco Human Plasma-like Medium (HPLM), Gibco CTS OpTmizer Pro Serum-free Media (SFM), and Gibco BenchStable Media. With its strong product portfolio, continuous research and development activities, and broad geographic reach, Thermo Fisher Scientific is expected to witness significant growth in the market.
Danaher Corporation (US) conducts its business through three segments, namely, Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences business segment offers cell culture media products under Cytiva. The company has a strong geographic presence with subsidiaries across North America, Europe, the Asia Pacific, Latin America, and Africa. Danaher also has a significant focus on strategic collaborations and acquisitions to strengthen its competitive position in the cell culture media market. For instance, in March 2020, Danaher completed the acquisition of General Electric’s Life Sciences Division and renamed it Cytiva to enhance its Life Sciences products and services portfolio.
Merck KGaA (Germany) operates through three business segments, namely, Healthcare, Life Science, and Performance Materials. The Life Science segment is further divided into research solutions, process solutions, and applied solutions subsegments. Merck provides cell culture media products through the research solutions and process solutions subsegments. Merck KGaA is one of the leading players in the cell culture media market. Its key strength lies in its strong product portfolio. The company adopts organic growth strategies such as expansions to increase its dominance in this market. In May 2019, the company completed the expansion to its Irvine biopharmaceutical production facility for the production of both powder and liquid cell culture media.
Cell Culture Media Market by Type(Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application(Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User(Pharma, Biotech) - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE